Developing Micro-RNA Therapeutics for Glioblastoma Patients
ABC2 became the first non-profit to partner with Regulus in an effort to expand their research portfolio to include brain cancer. They are now working with Samsung Medical Center to develop a microRNA therapeutic to target the “master control switches” in brain tumors.
Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus will apply its expertise in microRNA therapeutics to discover chemically modified oligonucleotide anti-miRs for testing at the Samsung Medical Center in preclinical models that mimic human brain cancer.
Accelerate Brain Cancer Cure is a Washington DC-based venture philanthropy 501(c)(3) nonprofit organization that drives cutting-edge research and treatments for brain tumors. Copyright 2014 ABC2 - All Rights Reserved.